Clinical Trial Search

Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…

Primary: Falls Self-Efficacy Scale-International (FES-I) Results — 13.07; 13.71; 13.41; 14.35 units on a scale — p=<0.05

Primary: Acceptability of Intervention Measure — 4.13; 4.25; 3.69; 4.31 score on a scale — p=0.905

Primary: Number of Participants With PrEP Initiation — 192; 120; 426 Participants — p=<.0001

Primary: Seroconversion Rate to HD- Versus SD-IV in People With RA — 12; 31 Participants

Primary: Area Under the Concentration-time Curve of BI 765080 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3528304.5; 7625263.8…

Primary: Phase Ib: Maximum Tolerated Dose — 4; 200 mg

Primary: Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03)…

Primary: The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study Vaccination — 1; 1; 2; 1…

Primary: Participants Enrolled — 36 Participants

Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.24; -1.63 score on a scale

Primary: Score on Knee Injury and Osteoarthritis Outcome Score (KOOS) Survey — 67; 69; 67.7 score on a scale

Primary: The Primary Outcome Measurement for This Study Was to Determine Differences in Center of Pressure (COP) and Static Postural Control Patterns in Individuals With and…

Primary: Qualitative Theme Among 28 Patients on Perspectives on Lethal Means Interventions — 26; 20; 24; 14 participants

Primary: Amount of Time Spent Looking at the Front-of-package Sodium Label (i.e., Dwell Time) — .96; 1.94; 2.34; 2.58 seconds — p=<0.001